Our Services
Medical Information
Helpful Resources
Published on: 6/17/2026
Age-related macular degeneration (AMD) treatment depends on the type. Dry AMD is managed with AREDS2 supplements, a diet rich in leafy greens and omega-3 fatty acids, blood pressure and weight control, and routine eye exams to track progression. Wet AMD requires anti-VEGF injections such as Lucentis, Eylea, or Avastin, and may also involve photodynamic or laser therapy to seal leaking blood vessels.
Below, you'll find key details on dosing schedules, follow-up care, treatment risks, and emerging therapies that could shape your next steps.
Because AMD symptoms can overlap with other vision conditions—and early intervention dramatically improves outcomes—it's worth taking a few minutes to clarify what you're experiencing before your next appointment. A free, instant, online symptom check can help you understand your symptoms and guide your next steps with confidence.
Reviewed for medical accuracy: 06/17/2026
Age-related macular degeneration (AMD) is a leading cause of vision loss in adults over 50. It damages the macula, the part of the eye responsible for sharp, central vision. There are two main forms:
While neither form can be cured, doctors use medical treatments and lifestyle changes to slow vision loss, preserve quality of life, and monitor for progression.
Regardless of whether AMD is wet or dry, some steps can help protect your eyes and overall health:
Quit smoking
Tobacco accelerates macular damage and increases AMD risk.
Healthy diet
Focus on green leafy vegetables, colorful fruits, fish rich in omega-3s, and nuts.
Maintain healthy weight and blood pressure
Obesity and hypertension can worsen AMD progression.
Regular eye exams
Early detection allows timely treatment.
Home monitoring
Use an Amsler grid daily to spot new distortions or dark areas in your central vision.
Protect your eyes from UV light
Wear sunglasses with UV protection when outdoors.
Dry AMD accounts for about 85–90% of all cases. Damage is slow but irreversible once cells die. Treatment focuses on nutritional support and close monitoring.
The National Eye Institute studied two formulations:
Key components:
Who benefits?
Wet AMD is more aggressive but highly responsive to treatments that block abnormal blood vessel growth. Early intervention is key to preserving vision.
VEGF (vascular endothelial growth factor) fuels abnormal vessel growth. Injecting anti-VEGF medications into the eye reduces leakage and stabilizes vision.
Common agents:
Treatment protocols:
Benefits and considerations:
Researchers are exploring new ways to slow or reverse AMD:
While promising, these treatments are still under study. Discuss clinical trial options with your ophthalmologist if you meet eligibility criteria.
If you're experiencing vision changes or distortions, you can use a free AI-powered symptom checker to assess your risk for Age-Related Macular Degeneration and determine whether you need to schedule an eye exam right away.
Always talk with your doctor or retinal specialist about the best combination of treatments for your situation. Early and consistent care is the most effective way to slow vision loss from both wet and dry AMD.
(References)
* Schmidt-Erfurth U, Waldstein SM, Ruetsch C, Tode J, Wagner L. Age-Related Macular Degeneration: An Update on Current Treatments. Cells. 2023 Jul 26;12(15):2001. doi: 10.3390/cells12152001. PMID: 37571871; PMCID: PMC10376179.
* Rosenfeld PJ, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Targeting Geographic Atrophy in Age-Related Macular Degeneration. Cells. 2022 Nov 17;11(22):3655. doi: 10.3390/cells11223655. PMID: 36459346; PMCID: PMC9676579.
* Brown DM, Singh RP, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Cells. 2022 Nov 16;11(22):3649. doi: 10.3390/cells11223649. PMID: 36459340; PMCID: PMC9676239.
* Khetpal V, Kim R, Lam BL, Yuan G, Lowy J, Zheng D. Advances in the Management of Age-Related Macular Degeneration. Cells. 2022 Nov 16;11(22):3645. doi: 10.3390/cells11223645. PMID: 36459336; PMCID: PMC9676226.
* Jager R, Singh R. Emerging Pharmacotherapies for Geographic Atrophy. J Clin Med. 2023 Nov 21;12(22):7309. doi: 10.3390/jcm12227309. PMID: 38002621; PMCID: PMC10670566.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.